Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer (Q64288089)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 March 2019

Language	Label	Description	Also known as
English	Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer	scientific article published on 01 March 2019

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

0 references

Early breast cancer

0 references

0 references

Maria Vittoria Dieci

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Pierfranco Conte

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Valentina Guarneri

22

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

author name string

G Bisagni

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

A A Brandes

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

A Frassoldati

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

L Cavanna

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

F Giotta

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

A Rimanti

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

O Garrone

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

E Bertone

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

K Cagossi

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

S Sarti

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

A Ferro

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

F Piacentini

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

A Maiorana

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

E Orvieto

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

M Sanders

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

F Miglietta

19

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

R D'Amico

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

language of work or name

0 references

publication date

1 March 2019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

30

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

418-423

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab containing regimens for early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immune system and response to HER2-targeted treatment in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Escalation and de-escalation in HER2 positive early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30657852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDZ007

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30657852%20AND%20SRC:MED&resulttype=core&format=json

19 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64288089&oldid=2002382755"